Patients With Typical Symptoms of GERD (GERD Q >= 8)
0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
AstraZenecaCAMBRIDGE, United Kingdom
1 programProton Pump Inhibitor Empirical Treatment in Management of Outpatients With Gastroesophageal Reflux N/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AstraZenecaProton Pump Inhibitor Empirical Treatment in Management of Outpatients With Gastroesophageal Reflux
Clinical Trials (1)
Total enrollment: 1,000 patients across 1 trials
NCT02606851AstraZenecaProton Pump Inhibitor Empirical Treatment in Management of Outpatients With Gastroesophageal Reflux
Proton Pump Inhibitor Empirical Treatment in Management of Outpatients With Gastroesophageal Reflux Disease.
Start: Dec 2015Est. completion: Dec 20161,000 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space